Baillie Gifford & Co
WST icon

Baillie Gifford & Co’s West Pharmaceutical WST Stock Holding History

Baillie Gifford & Co’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-46
Closed -$15.9K – 435
2023
Q1 		$15.9K Buy
46
+6
+15% +$1.75K ﹤0.01% 361
2022
Q4 		$9.41K Hold
40
– – ﹤0.01% 417
2022
Q3 		$10K Hold
40
– – ﹤0.01% 414
2022
Q2 		$12K Buy
+40
New +$13K ﹤0.01% 400

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $31.6B AUM 19.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
DCP
Durable Capital Partners Bethesda, Maryland $9.71B AUM 26.27% 1-Year Est. Return

Baillie Gifford & Co's WST Position: Q2 2023 in Review

Baillie Gifford & Co sold out of West Pharmaceutical (WST) in Q2 2023, closing a stake of 46 shares — an estimated $15.9K sold.

Baillie Gifford & Co first reported a position in WST in Q2 2022 and held it in 4 quarters. The position peaked at $15.9K in Q1 2023. 734 funds tracked by Wall St. Rank hold WST as of Q2 2023.

  • Baillie Gifford & Co reported no remaining West Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 46 West Pharmaceutical shares in Q2 2023, an estimated $15.9K.
  • Baillie Gifford & Co first reported a position in West Pharmaceutical in Q2 2022 and held it in 4 quarters.
  • Baillie Gifford & Co's West Pharmaceutical position peaked at $15.9K in Q1 2023.
  • 734 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.